EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction

Michael J Duffy

Tumor Biology · 19.03.2024 · 46 (s1) · S283-S295

DOI: 10.3233/tub-220044 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Tumor Biology, online erschienen am 26.05.2023. Verfasst von Michael J Duffy. Beteiligte Einrichtung: UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin and UCD School of Medicine, Conway Institute of Biomolecular and Biomedical R…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA), i.e., DNA shed from tumor cells into the bloodstream, is emerging as one of the most useful plasma biomarkers in patients with multiple types of cancer, including patients with non-small cell lung cancer (NSCLC). Indeed, NSCLC was the first malignancy in which measurement of ctDNA was approved for clinical use, i.e., mutational testing of EGFR for predicting response to EGFR tyrosine kinase inhibitors in patients with advanced disease. Although historically the gold standard method for EGFR mutational analysis required tumor tissue, the use of ctDNA is more convenient and safer for patients, results in a faster turn-around-time for return of results, provides a more complete representation of genetic alteration in heterogeneous tumors and is less costly to perform. Emerging uses of ctDNA in patients with lung or suspected lung cancer include screening for early disease, surveillance following initial treatment and monitoring response to therapy in metastatic disease. For evaluating therapy response, ctDNA appears to be especially useful in patients receiving targeted therapies against driver oncogenes or immunotherapy. Further work should not only validate these emerging findings but also aim to optimize and standardize ctDNA assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungCirculating Tumor DNAHumansErbB ReceptorsMutationBiomarkers, Tumor

Stichwörter der Autor:innen

LungbiomarkercancerctDNAliquid biopsytumor marker

Substanzen

Circulating Tumor DNAErbB ReceptorsBiomarkers, Tumor

Autor:innen und Institutionen

  • UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin and UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.

Zitieren

APA

Duffy, M. J. (2024). Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction. Tumor Biology, 46(s1), S283-S295. https://doi.org/10.3233/tub-220044

Vancouver

Duffy MJ. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction. Tumor Biology. 2024;46(s1):S283-S295. doi:10.3233/tub-220044

BibTeX
@article{Duffy2024,
  author = {Duffy, Michael J},
  title = {Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction},
  journal = {Tumor Biology},
  year = {2024},
  volume = {46},
  number = {s1},
  pages = {S283--S295},
  doi = {10.3233/tub-220044}
}
Kostenlos starten →